Page 73 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Rogers et al. J Transl Med (2020) 18:203 Page 19 of 19

230. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute ls/2020/Ather sys‑Provi des‑Updat e‑on‑One‑Year‑ARDS‑Study ‑Data/
respiratory distress syndrome with allogeneic adipose‑derived mesen‑ defau lt.aspx.
chymal stem cells: a randomized, placebo‑controlled pilot study. Respir 239. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and
Res. 2014;15(1):39. progression of acute respiratory distress syndrome in coronavirus
231. Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalen disease 2019. medRxiv. 2020. https ://doi.org/10.1101/2020.02.17.20024
M, et al. In vivo ef ects of mesenchymal stromal cells in two patients 166.
with severe acute respiratory distress syndrome. Stem Cells Transl Med. 240. Liang B CJ, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Nie P,
2015;4(10):1199–213. Gao Y, Qian C, Hu M. Clinical remission of a critically ill COVID‑19 patient
232. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, et al. treated by human umbilical cord mesenchymal stem cells 2020. http://
Plasma angiopoietin‑2 predicts the onset of acute lung injury in criti‑ china xiv.org/abs/20200 2.00084 .
cally ill patients. Am J Respir Crit Care Med. 2013;187(7):736–42. 241. Shetty AK. Mesenchymal stem cell infusion shows promise for combat‑
233. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA. Plasma ing coronavirus (COVID‑19)‑induced pneumonia. Aging and disease.
angiopoietin‑2 in clinical acute lung injury: prognostic and pathoge‑ 2020;11(2):462.
netic signif cance. Crit Care Med. 2012;40(6):1731–7. 242. Pluristem. Pluristem Reports Preliminary Data from its COVID‑19 Com‑
234. Zinter MS, Spicer A, Orwoll BO, Alkhouli M, Dvorak CC, Calfee CS, et al. passionate Use Program, Treating Seven Patients with Acute Respiratory
Plasma angiopoietin‑2 outperforms other markers of endothelial injury Failure 2020 [Clinical study results]. https ://www.pluri stem.com/wp‑
in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol conte nt/uploa ds/2020/04/PSTI‑PR‑Follo w‑up‑on‑Covid ‑19‑treat ments
Physiol. 2016;310(3):L224–31. ‑FINAL ‑FOR‑RELEA SE.pdf. Accessed 7 Apr 2020.
235. Gutbier BNA, Reppe K, et al. Prognostic and pathogenic role of 243. Sami T. Mesoblast reports 83% survival in ventilator‑dependent COVID‑
angiopoietin‑1 and ‑2 in pneumonia. Am J Respir Crit Care Med. 19 patients following stem cell therapy: BioWorld; 2020 [Preliminary
2018;198:220–31. clinical trial results]. https ://www.biowo rld.com/artic les/43464 0‑mesob
236. Bhandari V, Choo‑Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, last‑repor ts‑83‑survi val‑in‑venti lator ‑depen dent‑covid ‑19‑patie nts‑follo
et al. Hyperoxia causes angiopoietin 2‑mediated acute lung injury and wing‑stem‑cell‑thera py. Accessed 24 Apr 2020.
necrotic cell death. Nat Med. 2006;12(11):1286–93.
237. Parikh SM. Angiopoietins and Tie2 in vascular inf ammation. Curr Opin Publisher’s Note
Hematol. 2017;24(5):432–8.
238. Athersys. Athersys Provides Update on One‑Year ARDS Study Data 2020. Springer Nature remains neutral with regard to jurisdictional claims in pub‑
https ://www.ather sys.com/inves tors/press ‑relea ses/press ‑relea se‑detai lished maps and institutional af liations.

Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission

• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions